Personnel Information

写真a

KURATA Morito


Job title

Associate Professor

Mail Address

The inquiry by e-mail is 《here

Research Areas, Keywords

Leukemia, oncogene, drug resistance, CRISPR screening

Profile

My interest is the mechanism of tumorigenesis and drug resistance in leukemia. CRISPR screening is a powerful tool to clarify the new mechanisms of drug resistance. Comprehensive screening is one promising approach for identifying new oncogenic targets of cancer cell survival.

Graduating School 【 display / non-display

  • Fukui Medical University, Faculty of Medicine, 2003.03, Graduated

Graduate School 【 display / non-display

  • Tokyo Medical and Dental University, Doctor's Course, 2007.03, Completed

Campus Career 【 display / non-display

  • 2007.04
    -
    2013.03
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Comprehensive Pathology, Assistant Professor
  • 2013.04
    -
    2013.09
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Comprehensive Pathology, Junior Associate Professor
  • 2016.09
    -
    2024.03
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Comprehensive Pathology, Junior Associate Professor
  • 2024.04
    -
    Now
    Tokyo Medical and Dental University, Tokyo Medical and Dental University, Division of Integrated Facilities, Pathology, Associate Professor

External Career 【 display / non-display

  • 2013.10
    -
    2016.09
    University of Minnesota, Masonic Cancer Center, Visiting Associate Professor / Research Scholar

Research Areas 【 display / non-display

  • Pathological biochemistry

  • Experimental pathology

Qualification Acquired 【 display / non-display

  • Doctor

 

Published Papers & Misc 【 display / non-display

  1. Sugita K, Onishi I, Nakayama R, Ishibashi S, Ikeda M, Inoue M, Narita R, Oshima S, Shimizu K, Saito S, Sato S, Moriarity BS, Yamamoto K, Largaespada DA, Kitagawa M, Kurata M. Indirect CRISPR screening with photoconversion revealed key factors of drug resistance with cell-cell interactions. Communications biology. 2023.06; 6 (1): 582. ( PubMed, DOI )

  2. Morito Kurata, Marie Lue Antony, Klara E Noble-Orcutt, Susan K Rathe, Yoonkyu Lee, Hidehiro Furuno, Sachiko Ishibashi, Masumi Ikeda, Kouhei Yamamoto, Masanobu Kitagawa, David A Largaespada, Zohar Sachs. Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line. Mol Cancer Res. 2022.11; 20 (11): 1646-1658. ( PubMed, DOI )

  3. Morito Kurata, Iichiro Onishi, Tomoko Takahara, Yukari Yamazaki, Sachiko Ishibashi, Ryo Goitsuka, Daisuke Kitamura, Junko Takita, Yasuhide Hayashi, David A Largaesapda, Masanobu Kitagawa, Takuro Nakamura. C/EBPβ induces B-cell acute lymphoblastic leukemia and cooperates with BLNK mutations. Cancer Sci. 2021.12; 112 (12): 4920-4930. ( PubMed, DOI )

  4. Yamamoto Akiko, Kurata Morito, Onishi Iichiroh, Sugita Keisuke, Matsumura Miwa, Ishibashi Sachiko, Ikeda Masumi, Yamamoto Kouhei, Kitagawa Masanobu. CRISPR screening identifies M1AP as a new MYC regulator with a promoter-reporter system PEERJ. 2020.05; 8 e9046. ( PubMed, DOI )

  5. Morito Kurata, Natalie K Wolf, Walker S Lahr, Madison T Weg, Mitchell G Kluesner, Samantha Lee, Kai Hui, Masano Shiraiwa, Beau R Webber, Branden S Moriarity. Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays. PLoS ONE. 2018.09; 13 (9): e0198714. ( PubMed, DOI )

  6. Umemori M, Kurata M, Yamamoto A, Yamamoto K, Ishibashi S, Ikeda M, Tashiro K, Kimura T, Sato S, Takahashi H, Kitagawa M. The expression of MYC is strongly dependent on the circular PVT1 expression in pure Gleason pattern 4 of prostatic cancer. Medical molecular morphology. 2020.01; ( PubMed, DOI )

  7. Morito Kurata, Susan K Rathe, Natashay J Bailey, Natalie K Aumann, Justine M Jones, G Willemijn Veldhuijzen, Branden S Moriarity, David A Largaespada. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML. Sci Rep. 2016.11; 6 36199. ( PubMed, DOI )

  8. Yamamoto A, Kurata M, Yamamoto K, Nogawa D, Inoue M, Ishibashi S, Ikeda M, Miyasaka N, Kitagawa M. High amplification of PVT1 and MYC predict favorable prognosis in early ovarian carcinoma. Pathology, research and practice. 2020.08; 216 (11): 153175. ( PubMed, DOI )

  9. Murakami, M; Hara, K; Ikeda, K; Horino, M; Okazaki, R; Niitsu, Y; Takeuchi, A; Aoki, J; Shiba, K; Tsujimoto, K; Komiya, C; Nakamura, Y; Kurata, M; Akashi, T; Fujii, Y; Yamada, T. Single-Nucleus Analysis Reveals Tumor Heterogeneity of Aldosterone-Producing Adenoma HYPERTENSION. 2024.02; 81 (2): 361-371. ( PubMed, DOI )

  10. Kawade G, Kurata M, Matsuki Y, Fukuda S, Onishi I, Kinowaki Y, Watabe S, Ishibashi S, Ikeda M, Yamamoto M, Ohashi K, Kitagawa M, Yamamoto K. Mediation of Ferroptosis Suppressor Protein 1 Expression via 4-Hydroxy-2-Nonenal Accumulation Contributes to Acquisition of Resistance to Apoptosis and Ferroptosis in Diffuse Large B-Cell Lymphoma. Laboratory investigation; a journal of technical methods and pathology. 2024.02; 104 (4): 102027. ( PubMed, DOI )

  11. Kinowaki Y, Fukumura Y, Kawade G, Sugita K, Kinowaki K, Akahoshi K, Kobayashi M, Ono H, Kudo A, Tanabe M, Akashi T, Ohashi K, Kurata M. Gene expression profiling of pancreatic neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm. Gene. 2024.01; 893 147916. ( PubMed, DOI )

  12. Watabe, S; Aruga, Y; Kato, R; Kawade, G; Kubo, Y; Tatsuzawa, A; Onishi, I; Kinowaki, Y; Ishibashi, S; Ikeda, M; Fukawa, Y; Akahoshi, K; Tanabe, M; Kurata, M; Ohashi, K; Kitagawa, M; Yamamoto, K. Regulation of 4-HNE via SMARCA4 Is Associated with Worse Clinical Outcomes in Hepatocellular Carcinoma BIOMEDICINES. 2023.08; 11 (8): ( PubMed, DOI )

  13. Nonaka Keisuke, Kurata Morito, Tachibana Moriaki, Komatsu Akiko, Shichi Yuuki, Gomi Fujiya, Ishiwata Toshiyuki, Miyamoto Kou, Arai Tomio. 異なる解剖学的部位で免疫グロブリン軽鎖制限の不一致が認められたクローン性B細胞リンパ腫の染色体分析(Chromosomal analysis of clonally related B-cell lymphomas with discordant immunoglobulin light-chain restrictions at different anatomical sites) Pathology International. 2023.02; 73 (2): 100-102. ( ichushi )

  14. Koyanagi, A; Onishi, I; Muraoka, K; Sato, I; Sato, S; Kimura, T; Kishida, A; Yamamoto, K; Kitagawa, M; Kurata, M. Identification of the Factor That Leads Human Mesenchymal Stem Cell Lines into Decellularized Bone BIOENGINEERING-BASEL. 2022.10; 9 (10): ( PubMed, DOI )

  15. Shinohara H, Kobayashi M, Hayashi K, Nogawa D, Asakawa A, Ohata Y, Kubota K, Takahashi H, Yamada M, Tokunaga M, Kinugasa Y, Oda G, Nakagawa T, Onishi I, Kinowaki Y, Kurata M, Ohashi K, Kitagawa M, Yamamoto K. Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable Clinical Outcomes in Triple-Negative Breast Cancer. International journal of molecular sciences. 2022.10; 23 (21): ( PubMed, DOI )

  16. Koyanagi A, Onishi I, Muraoka K, Sato I, Sato S, Kimura T, Kishida A, Yamamoto K, Kitagawa M, Kurata M. Identification of the Factor That Leads Human Mesenchymal Stem Cell Lines into Decellularized Bone. Bioengineering (Basel, Switzerland). 2022.09; 9 (10):

  17. Ueno H, Yamaoka H, Hirai S, Fujita K, Ishikawa M, Fujii S, Aizawa Y, Ishii Y, Yoshimura M, Yamada K, Yoshino Y, Kurata M, Seto K, Ishibashi H, Okubo K, Nemoto S, Sumita K. Endovascular treatment for acute ischemic stroke after video-assisted thoracoscopic pulmonary lobectomy in patients with lung cancer: A report of four cases and literature review. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2022.06; 31 (8): 106593. ( PubMed, DOI )

  18. Asakawa, A; Kawade, G; Kurata, M; Fukuda, S; Onishi, I; Kinowaki, Y; Ishibashi, S; Ikeda, M; Watabe, S; Kobayashi, M; Ishibashi, H; Okubo, K; Kitagawa, M; Yamamoto, K. Stratification of lung squamous cell carcinoma based on ferroptosis regulators: Potential for new therapeutic strategies involving ferroptosis induction LUNG CANCER. 2022.03; 165 82-90. ( PubMed, DOI )

  19. Hayashi K, Nogawa D, Kobayashi M, Asakawa A, Ohata Y, Kitagawa S, Kubota K, Takahashi H, Yamada M, Oda G, Nakagawa T, Uetake H, Onishi I, Kinowaki Y, Kurata M, Kitagawa M, Yamamoto K. Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer. Frontiers in oncology. 2022; 12 901591. ( PubMed, DOI )

  20. Onishi I, Yamamoto K, Kinowaki Y, Kitagawa M, Kurata M. To Discover the Efficient and Novel Drug Targets in Human Cancers Using CRISPR/Cas Screening and Databases. International journal of molecular sciences. 2021.11; 22 (22): ( PubMed, DOI )

  21. Sekine Y, Yamamoto K, Kurata M, Honda A, Onishi I, Kinowaki Y, Kawade G, Watabe S, Nomura S, Fukuda S, Ishibashi S, Ikeda M, Yamamoto M, Kitagawa M. HADHB, a fatty acid beta-oxidation enzyme, is a potential prognostic predictor in malignant lymphoma. Pathology. 2021.09; 54 (3): 286-293. ( PubMed, DOI )

  22. Yoshimori M, Shibayama H, Imadome KI, Kawano F, Ohashi A, Nishio M, Shimizu N, Kurata M, Fujiwara S, Arai A. Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection. Blood advances. 2021.04; 5 (7): 1805-1815. ( PubMed, DOI )

  23. Fukui T, Chochi T, Maeda T, Lee C, Wada Y, Ohashi M, Tashiro J, Arai M, Kurata M, Yoshida T, Konishi F. Biliary Peritonitis Caused by Spontaneous Bile Duct Rupture in the Left Triangular Ligament of the Liver after Endoscopic Sphincterotomy for Choledocholithiasis. Case reports in gastroenterology. 2021.01; 15 (1): 53-61. ( PubMed, DOI )

  24. Taguchi Towako, Kurata Morito, Onishi Iichiroh, Kinowako Yuko, Sato Yunosuke, Shiono Sayuri, Ishibashi Sachiko, Ikeda Masumi, Yamamoto Masahide, Kitagawa Masanobu, Yamamoto Kouhei. SECISBP2 is a novel prognostic predictor that regulates selenoproteins in diffuse large B-cell lymphoma LABORATORY INVESTIGATION. 2020.10; ( PubMed, DOI )

  25. Yanai Masae, Kurata Morito, Muto Yutaka, Iha Hiroto, Kanao Toshinori, Tatsuzawa Anna, Ishibashi Sachiko, Ikeda Masumi, Kitagawa Masanobu, Yamamoto Kouhei. Clinicopathological and molecular analysis of SIRT7 in hepatocellular carcinoma PATHOLOGY. 2020.08; 52 (5): 529-537. ( PubMed, DOI )

  26. Kitagawa M, Kurata M, Onishi I, Yamamoto K. Bone marrow niches in myeloid neoplasms. Pathology international. 2019.11; ( PubMed, DOI )

  27. Yamamoto K, Abe S, Honda A, Hashimoto J, Aizawa Y, Ishibashi S, Takemura T, Hanagata N, Yamamoto M, Miura O, Kurata M, Kitagawa M. Fatty acid beta oxidation enzyme HADHA is a novel potential therapeutic target in malignant lymphoma. Laboratory investigation; a journal of technical methods and pathology. 2019.09; 100 (3): 353-362. ( PubMed, DOI )

  28. Camilleri Emily T., Beckmann Pauli J., Larson Jon D., Kurata Morito, Shu Jingmin, Pope Emily, Hudson Wendy A., Temiz Nuri A., Rathe Susan K., LaRue Rebecca S., Sarver Anne E., Scott Milcah C., Varshney Jyotika, Modiano Jaime F., Moriarity Branden S., Sarver Aaron L., Seshagiri Somasekar, Largaespada David A.. RNA sequencing based analysis of transposon-induced tumors reveals novel insights into cancer pathogenesis and progression CANCER RESEARCH. 2018.07; 78 (13): ( DOI )

  29. Gulinisha Aihemaiti, Morito Kurata, Daichi Nogawa, Akiko Yamamoto, Tatsunori Mineo, Iichiroh Onishi, Yuko Kinowaki, Xiao-Hai Jin, Anna Tatsuzawa, Naoyuki Miyasaka, Masanobu Kitagawa, Kouhei Yamamoto. Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma. Oncotarget. 2018.06; 9 (46): 28213-28225. ( PubMed, DOI )

  30. Maria Razzoli, Kewir Nyuyki-Dufe, Allison Gurney, Connor Erickson, Jacob McCallum, Nicholas Spielman, Marta Marzullo, Jessica Patricelli, Morito Kurata, Emily A Pope, Chadi Touma, Rupert Palme, David A Largaespada, David B Allison, Alessandro Bartolomucci. Social stress shortens lifespan in mice. Aging Cell. 2018.05; e12778. ( PubMed, DOI )

  31. Yuko Kinowaki, Morito Kurata, Sachiko Ishibashi, Masumi Ikeda, Anna Tatsuzawa, Masahide Yamamoto, Osamu Miura, Masanobu Kitagawa, Kouhei Yamamoto. Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. Lab. Invest.. 2018.02; ( PubMed, DOI )

  32. Morito Kurata, Kouhei Yamamoto, Branden S Moriarity, Masanobu Kitagawa, David A Largaespada. CRISPR/Cas9 library screening for drug target discovery. J. Hum. Genet.. 2018.02; 63 (2): 179-186. ( PubMed, DOI )

  33. Miyamoto Norikazu, Kurata Morito, Nagiri Toshiya, Abe Shinya, Yamamoto Kouhei, Onishi Iichiroh, Kirimura Susumu, Murayama Toshihiko, Hidaka Michihiro, Kitagawa Masanobu. Differential expression of ACINUS variants in bone marrow in myelodysplastic syndromes INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY. 2017; 10 (4): 4330-4338.

  34. Susumu Kirimura, Morito Kurata, Yasunori Nakagawa, Iichiroh Onishi, Shiho Abe-Suzuki, Shinya Abe, Kouhei Yamamoto, Masanobu Kitagawa. Role of microRNA-29b in myelodysplastic syndromes during transformation to overt leukaemia. Pathology. 2016.04; 48 (3): 233-241. ( PubMed, DOI )

  35. Kouhei Yamamoto, Yukako Miwa, Shiho Abe-Suzuki, Shinya Abe, Susumu Kirimura, Iichiroh Onishi, Masanobu Kitagawa, Morito Kurata. Extramedullary hematopoiesis: Elucidating the function of the hematopoietic stem cell niche (Review). Mol Med Rep. 2016.01; 13 (1): 587-591. ( PubMed, DOI )

  36. Mayumi Yoshimori, Honami Takada, Ken-Ichi Imadome, Morito Kurata, Kouhei Yamamoto, Takatoshi Koyama, Norio Shimizu, Shigeyoshi Fujiwara, Osamu Miura, Ayako Arai. P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases. Cancer Med. 2015.10; 4 (10): 1494-1504. ( PubMed, DOI )

  37. Shinya Abe, Kouhei Yamamoto, Morito Kurata, Shiho Abe-Suzuki, Rie Horii, Futoshi Akiyama, Masanobu Kitagawa. Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors. Oncotarget. 2015.10; 6 (33): 34892-34909. ( PubMed, DOI )

  38. Jinta M, Imadome K, Komatsu H, Yoshimori M, Kurata M, Fujiwara S, Miura O, Arai A.. L-Asparaginase monotherapy for EBV-positive T/NK lymphoproliferative diseases: A pilot Study. Journal of Medical and Dental Sciences. 2015.03; 62 (1): 1-9. ( DOI )

  39. Iichiroh Onishi, Yasunori Nakagawa, Toshihiko Murayama, Michihiro Hidaka, Kouhei Yamamoto, Shiho Abe-Suzuki, Shinya Abe, Morito Kurata, Masanobu Kitagawa. Expression of multidrug resistance 1 gene in association with CXCL12 in chronic myelogenous leukaemia. Pathology. 2014.12; 46 (7): 623-629. ( PubMed, DOI )

  40. Shiho Abe-Suzuki, Morito Kurata, Shinya Abe, Iichiroh Onishi, Susumu Kirimura, Manami Nashimoto, Toshihiko Murayama, Michihiro Hidaka, Masanobu Kitagawa. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. Lab. Invest.. 2014.11; 94 (11): 1212-1223. ( PubMed, DOI )

  41. Susan K Rathe, Branden S Moriarity, Christopher B Stoltenberg, Morito Kurata, Natalie K Aumann, Eric P Rahrmann, Natashay J Bailey, Ellen G Melrose, Dominic A Beckmann, Chase R Liska, David A Largaespada. Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia. Sci Rep. 2014.08; 4 6048. ( PubMed, DOI )

  42. Mayumi Yoshimori, Ken-Ichi Imadome, Honami Komatsu, Ludan Wang, Yasunori Saitoh, Shoji Yamaoka, Tetsuya Fukuda, Morito Kurata, Takatoshi Koyama, Norio Shimizu, Shigeyoshi Fujiwara, Osamu Miura, Ayako Arai. CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals. PLoS ONE. 2014; 9 (11): e112564. ( PubMed, DOI )

  43. Taira N, Mimoto R, Kurata M, Yamaguchi T, Kitagawa M, Miki Y, Yoshida K. DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. J Clin Invest. 2012.03; 122 (3): 859-872. ( PubMed, DOI )

  44. Suzuki S, Kurata M, Abe S, Miyazawa R, Murayama T, Hidaka M, Yamamoto K, Kitagawa M. Overexpression of MCM2 in myelodysplastic syndromes: Association with bone marrow cell apoptosis and peripheral cytopenia. Exp Mol Pathol. 2012.02; 92 (1): 160-166. ( PubMed, DOI )

  45. Okada Y, Kamata S, Akashi T, Kurata M, Nakamura T, Kihara K. Primitive neuroectodermal tumor/Ewing's sarcoma of the urinary bladder: a case report and its molecular diagnosis. Int J Clin Oncol. 2011.08; 16 (4): 435-438. ( PubMed, DOI )

  46. Hirooka S, Akashi T, Ando N, Suzuki Y, Ishida N, Kurata M, Takizawa T, Kayamori K, Sakamoto K, Fujiwara N, Kojima M, Eishi Y. Localization of the invadopodia-related proteins actinin-1 and cortactin to matrix-contact-side cytoplasm of cancer cells in surgically resected lung adenocarcinomas. Pathobiology. 2011; 78 (1): 10-23. ( PubMed, DOI )

  47. Kitagawa M, Kurata M, Yamamoto K, Abe S, Suzuki S, Umeda S. Molecular pathology of myelodysplastic syndromes: biology of medullary stromal and hematopoietic cells (review). Mol Med Report. 2011; 4 (4): 591-596. ( PubMed, DOI )

  48. Kurata M, Yamazaki Y, Kanno Y, Ishibashi S, Takahara T, Kitagawa M, Nakamura T. Anti-apoptotic function of Xbp1 as an IL-3 signaling molecule in hematopoietic cells. Cell Death Dis. 2011; 2 e118. ( PubMed, DOI )

  49. Smith TJ, Yamamoto K, Kurata M, Yukimori A, Suzuki S, Umeda S, Sugawara E, Kojima Y, Sawabe M, Nakagawa Y, Suzuki K, Crawley JT, Kitagawa M. Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Exp Mol Pathol. 2010.12; 89 (3): 284-290. ( PubMed, DOI )

  50. Kuninaka N, Kurata M, Yamamoto K, Suzuki S, Umeda S, Kirimura S, Arai A, Nakagawa Y, Suzuki K, Kitagawa M. Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia. Exp Mol Pathol. 2010.04; 88 (2): 293-298. ( PubMed, DOI )

  51. Uchihara T, Ohashi K, Kitagawa M, Kurata M, Nakamura A, Hirokawa K, Kasuga T, Kobayashi T. Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia. Acta Neuropathol. 2010.01; 119 (1): 135-145. ( PubMed, DOI )

  52. Toru S, Uchihara T, Takahashi M, Ichihara K, Endo T, Kurata M, Kitagawa M, Hirokawa K, Kobayashi T. Depletion or preservation of cardiac sympathetic nerve - an autopsy-verified contrast in two cases of Alzheimer's disease with or without Lewy bodies. Eur Neurol. 2010; 64 (3): 129-133. ( PubMed, DOI )

  53. Hasegawa M, Kurata M, Yamamoto K, Yoshida K, Aizawa S, Kitagawa M. A novel role for acinus and MCM2 as host-specific signaling enhancers of DNA-damage-induced apoptosis in association with viral protein gp70. Leuk Res. 2009.08; 33 (8): 1100-1107. ( PubMed, DOI )

  54. Konstantinou K, Yamamoto K, Ishibashi F, Mizoguchi Y, Kurata M, Nakagawa Y, Suzuki K, Sawabe M, Ohta M, Miyakoshi S, Crawley JT, Kitagawa M. Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol. 2009.03; 144 (5): 696-704. ( PubMed, DOI )

  55. Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, Yamamoto S, Migita T, Ishikawa Y, Kurata M, Nakamura T, Fukui I. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009.02; 15 (4): 1170-1176. ( PubMed, DOI )

  56. Shiraishi J, Nakagawa Y, Kurata M, Yamamoto K, Abe Y, Toyoda Y, Suzuki K, Kitagawa M, Takemura T. Follicular lymphoma with marked infiltration of eosinophils. Pathol Int. 2008.11; 58 (11): 701-705. ( PubMed, DOI )

  57. Kurata M, Nakagawa Y, Yamamoto K, Suzuki K, Kitagawa M. Induction of integrin beta1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma. Am J Hematol. 2008.09; 83 (9): 755-757. ( PubMed, DOI )

  58. Abe S, Hasegawa M, Yamamoto K, Kurata M, Nakagawa Y, Suzuki K, Takizawa T, Kitagawa M. Rapid induction of IAP family proteins and Smac/DIABLO expression after proapoptotic stimulation with doxorubicin in RPMI 8226 multiple myeloma cells. Exp Mol Pathol. 2007.12; 83 (3): 405-412. ( PubMed, DOI )

  59. Keith T, Araki Y, Ohyagi M, Hasegawa M, Yamamoto K, Kurata M, Nakagawa Y, Suzuki K, Kitagawa M. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol. 2007.05; 137 (3): 206-215. ( PubMed, DOI )

  60. Kurata M, Hasegawa M, Nakagawa Y, Abe S, Yamamoto K, Suzuki K, Kitagawa M. Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes. Exp Mol Pathol. 2006.12; 81 (3): 249-254. ( PubMed, DOI )

  61. Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, Takemura T, Suzuki K, Kitagawa M. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol. 2006.11; 81 (11): 824-831. ( PubMed, DOI )

  62. Abe S, Yamamoto K, Hasegawa M, Inoue M, Kurata M, Hirokawa K, Kitagawa M, Nakagawa Y, Suzuki K. Bone marrow cells of myelodysplastic syndromes exhibit significant expression of apollon, livin and ILP-2 with reduction after transformation to overt leukemia. Leuk Res. 2005.09; 29 (9): 1095-1096. ( PubMed, DOI )

  63. Kitagawa M, Utsuyama M, Kurata M, Yamamoto K, Yuasa Y, Ishikawa Y, Arai T, Hirokawa K. Cancer and aging: symposium of the 27th annual meeting of the Japanese society for biomedical gerontology, Tokyo. Cancer Immunol Immunother. 2005.07; 54 (7): 623-634. ( PubMed, DOI )

  64. Nakagawa Y, Hasegawa M, Kurata M, Yamamoto K, Abe S, Inoue M, Takemura T, Hirokawa K, Suzuki K, Kitagawa M. Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL). Am J Hematol. 2005.03; 78 (3): 173-180. ( PubMed, DOI )

  65. Yamamoto K, Abe S, Nakagawa Y, Suzuki K, Hasegawa M, Inoue M, Kurata M, Hirokawa K, Kitagawa M. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res. 2004.11; 28 (11): 1203-1211. ( PubMed, DOI )

  66. Nagano T, Nakamura A, Konno D, Kurata M, Yagi H, Sato M. A2-Pancortins (Pancortin-3 and -4) are the dominant pancortins during neocortical development. J Neurochem. 2000.07; 75 (1): 1-8. ( PubMed )

▼display all

Conference Activities & Talks 【 display / non-display

  1. 野上 彩子, 倉田 盛人, 田口 登和子, 小山 祥美, 永野 勝稔, 田中 圭祐, 吉藤 康太, 梅澤 佳央, 市村 直也, 東田 修二, 森 毅彦. 尿セルブロックを用いた出血性膀胱炎起因ウイルスの病理学的同定法の有用性. 日本血液学会学術集会 2023.10.01

  2. 大西 威一郎, 倉田 盛人, 大橋 健一. CRISPR screeningデータベースを用いた、遺伝性乳癌の新たな合成致死因子の探索(Identification of synthetic lethal genes of hereditary breast cancer using CRISPR screening database). 日本癌学会総会記事 2023.09.01

  3. 田村 一洋, 山本 浩平, 渡部 紫織, 川出 玄二, 大西 威一郎, 木脇 祐子, 石橋 佐知子, 池田 真住, 倉田 盛人, 大橋 健一. 肝細胞癌(HCC)における4-hydroxynonenal(4-HNE)の臨床病理学的および分子生物学的検討(Clinicopathological and molecular analysis of 4-hydroxynonenal(4-HNE) in Hepatocellular carcinoma). 日本病理学会会誌 2023.03.01

  4. 杉田 佳祐, 倉田 盛人, 大西 威一郎, 山本 浩平, 北川 昌伸. CRISPR screeningを用いた細胞間相互作用により誘導される薬剤耐性関連分子の同定(CRISPR screening revealed a new molecule of cell-cell interaction drug resistance.). 日本癌学会総会記事 2022.09.01

  5. 大西 威一郎, 小柳 杏莉, 村岡 香琳, 木村 剛, 岸田 晶夫, 北川 昌伸, 倉田 盛人. 脱細胞化骨を用いた、ヒト骨髄微小環境モデルの構築(Establishment of human bone-marrow microenvironment model using Decellularized bone). 日本癌学会総会記事 2022.09.01

  6. 大橋 彩香, 倉田 盛人, 新井 文子. EBV陽性T,NK細胞腫瘍、慢性活動性EBV感染症に対するBCL2阻害剤の効果(The Effects of BCL2 Inhibitors on Chronic Active EBV Infections, an Intractable T- or NK-cell Lymphoid Neoplasm). 日本癌学会総会記事 2022.09.01

  7. 山本 浩平, 川出 玄二, 石橋 佐知子, 倉田 盛人, 大西 威一郎, 北川 昌伸. Diffuse large B-cell lymphomaにおける4-HNE蓄積の臨床病理学的・分子学的意義(Clinico-pathologic and molecular significance of 4-HNE accumulation in diffuse large B-cell lymphoma). 日本病理学会会誌 2022.03.01

  8. 川出 玄二, 山本 浩平, 浅川 文香, 大西 威一郎, 倉田 盛人, 北川 昌伸. 肺癌におけるGPX4,FSP1発現と4-HNE蓄積の臨床病理学的検討(Clinicopathological study of GPX4 and FSP1 expression and 4HNE accumulation in lung cancer). 日本病理学会会誌 2022.03.01

  9. Morito Kurata, JP-AID. Establishing the database to utilize pooled whole slide images - Japan Pathology Artificial Intelligence Diagnostics Project (JP-AID)". The 12th Asia Pacific International Academy of Pathology Congress 2021.11.12 Okayama, Japan

  10. 田中 陽典, 倉田 盛人, 上林 秀孝, 山本 亜希子, 山本 浩平, 大西 威一郎, 北川 昌伸. CRISPR activation libraryを用いたMYCの発現調節因子の探求. 日本癌学会総会記事 2021.09.01

  11. 山本 浩平, 川出 玄二, 松木 裕子, 福田 翔, 倉田 盛人, 大西 威一郎, 北川 昌伸. Diffuse large B-cell lymphomaにおける4-HNEの蓄積の臨床病理学的・分子生物学的意義. 日本癌学会総会記事 2021.09.01

  12. 大西 威一郎, 倉田 盛人, 村岡 香琳, 小柳 杏莉, 木村 剛, 岸田 晶夫, 山本 浩平, 北川 昌伸. 脱細胞化骨を用いた、ヒト骨髄微小環境構築の試み. 日本癌学会総会記事 2021.09.01

  13. 川出 玄二, 山本 浩平, 福田 翔, 大西 威一郎, 倉田 盛人, 北川 昌伸. 肺扁平上皮癌におけるGPX4、FSP1発現と4HNE蓄積の臨床病理学的検討. 日本癌学会総会記事 2021.09.01

  14. 渡部 紫織, 山本 浩平, 倉田 盛人, 大西 威一郎, 川出 玄二, 北川 昌伸. 肝細胞癌における4-hydroxynonenal蓄積の臨床病理学的および分子生物学的研究. 日本癌学会総会記事 2021.09.01

  15. 杉田 佳祐, 倉田 盛人, 成田 莉菜, 大西 威一郎, 山本 浩平, 北川 昌伸. CRISPR KO Libraryを用いた細胞間相互作用により誘導される薬剤耐性機序の解明を目指して. 日本癌学会総会記事 2021.09.01

  16. Largaespada David A., Kurata Morito, Pope Emily A., Beckmann Pauli J., Larson Jon D., Shu Jingmin, Temiz Nuri A., Sarver Aaron L., Seshagiri Somasekar. RNA sequencingにより、transposon mutagenesisに誘発されるマウス腫瘍の"molecular pathology"が明らかになる(RNA sequencing reveals the "molecular pathology" of mouse tumors induced by transposon mutagenesis). 日本病理学会会誌 2021.03.01

  17. 倉田 盛人, 大西 威一郎, 山本 浩平, 北川 昌伸. CRISPR libraryを用いたNRAS発現調整可能THP-1細胞株によるシグナル解析. 日本癌学会総会記事 2020.10.01

  18. 田口 登和子, 山本 浩平, 木脇 祐子, 大西 威一郎, 倉田 盛人, 山本 正英, 北川 昌伸. びまん性大細胞性リンパ腫においてSECISBP2はセレノプロテインを調整する新規の予後予測因子になりうる. 日本癌学会総会記事 2020.10.01

  19. 川出 玄二, 山本 浩平, 立澤 杏奈, 矢内 雅恵, 倉田 盛人, 北川 昌伸. 肝細胞癌におけるGPX4発現の臨床病理学的検討. 日本癌学会総会記事 2020.10.01

  20. 大西 威一郎, 倉田 盛人, 山本 浩平, 木村 剛, 岸田 晶夫, 北川 昌伸. 脱細胞化骨を用いた、ヒト骨髄微小環境再構築の試み. 日本癌学会総会記事 2020.10.01

  21. 倉田 盛人, 大西 威一郎, 山本 浩平, 北川 昌伸. CRISPR libraryを用いたNRAS発現調整可能THP-1細胞株によるシグナル解析. 日本癌学会総会記事 2020.10.01

  22. 倉田 盛人, 山本 浩平, 北川 昌伸. PI3K変異型乳癌における新規協調癌遺伝子とシグナル探索(Discovery of cancer genes and pathways operative in PI3K activated mammary cancer). 日本癌学会総会記事 2019.09.01

  23. 野川 大地, グリニサ・アヒマティ , 山本 阿紀子, 大西 威一郎, 倉田 盛人, 宮坂 尚幸, 山本 浩平, 北川 昌伸. 卵巣癌におけるMCM2タンパクの細胞内局在に着目した臨床病理学的検討(Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma). 日本癌学会総会記事 2019.09.01

  24. 山本 浩平, 阿部 晋也, 倉田 盛人, 本田 彩華, 山本 正英, 北川 昌伸. ラノラジンは難治性悪性リンパ腫に対する有望な抗腫瘍薬としての可能性を有する(Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma). 日本癌学会総会記事 2019.09.01

  25. 野川 大地, グリニサ・アヒマティ , 山本 阿紀子, 立澤 杏奈, 峰尾 竜徳, 大西 威一郎, 倉田 盛人, 宮坂 尚幸, 山本 浩平, 北川 昌伸. 卵巣癌におけるMCM2タンパクの細胞内局在に着目した臨床病理学的検討(Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma). 日本病理学会会誌 2019.04.01

  26. 山本 浩平, 阿部 晋也, 本田 彩華, 山本 正英, 三浦 修, 倉田 盛人, 北川 昌伸. ラノラジンは難治性悪性リンパ腫に対する有望な抗腫瘍薬としての可能性を有する(Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma). 日本病理学会会誌 2019.04.01

  27. 野川 大地, グリニサ・アヒマティ , 山本 阿紀子, 大西 威一郎, 倉田 盛人, 宮坂 尚幸, 山本 浩平, 北川 昌伸. 卵巣癌におけるMCM2タンパクの細胞内局在に着目した臨床病理学的検討(Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma). 日本癌学会総会記事 2018.09.01

  28. 倉田 盛人, 山本 浩平, 北川 昌伸. NRAS発現調整可能システムとシグナルの解析(Controllable NRAS expression system and analysis of different signals). 日本癌学会総会記事 2018.09.01

  29. 山本 浩平, 阿部 晋也, 倉田 盛人, 本田 彩華, 山本 正英, 北川 昌伸. ラノラジンは難治性悪性リンパ腫に対する有望な抗腫瘍薬としての可能性を有する(Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma). 日本癌学会総会記事 2018.09.01

▼display all

 

Social Contribution 【 display / non-display

  • Guest editor,International Journal of Molecular Sciences,2021.08 - 2022.08